Tilray® Boosts International Export Capacity with Manufacturing License and GMP Certification at EU Campus
May 23 2019 - 8:00AM
Business Wire
Licensing and certification enhances
company’s capacity to export medical cannabis from Portugal to
Germany, other EU member states and international markets
Tilray, Inc. (“Tilray” or “the Company”) (NASDAQ:TLRY), a global
pioneer in cannabis research, cultivation, production and
distribution, today announced that its wholly-owned subsidiary
Tilray Portugal Unipessoal Lda. (“Tilray Portugal”) has received a
standard manufacturing license and a Good Manufacturing Practices
(GMP) certification, in accordance with the European Medicines
Agency’s (EMA) standards, for its Biocant Park manufacturing
facility in Cantanhede, Portugal. This license and certification
allow Tilray Portugal to manufacture and export GMP-certified dried
cannabis as an active substance for medicinal products.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190523005139/en/
Tilray has established sales and distribution arrangements to
supply medical cannabis through major pharmaceutical distribution
channels throughout Germany and the European Union (EU). This
license and certification further enhances Tilray’s capacity to
serve international markets such as Germany and other EU member
states, as well as none-EU jurisdictions that recognize EU GMP
certification.
Tilray’s EU Campus in Portugal is a multi-faceted production
facility that includes indoor, outdoor and greenhouse cultivation
sites; research and quality control labs; as well as processing,
packaging and distribution sites for medical cannabis and
cannabinoid-containing medical products. To date, Tilray has
invested approximately €20 million in the facility, which totals
nearly 250,000 square feet with additional room to expand. The site
also serves as a hub supporting Tilray’s clinical research and
product development efforts across Europe. The Tilray EU Campus
currently employs over 100 people, and that number is expected to
double by the end of 2019, with production ramping up and multiple
harvests anticipated in the coming months. An official
ribbon-cutting ceremony celebrating the inauguration of Tilray’s EU
Campus was hosted in April 2019.
“This licensing and certification marks a critical milestone for
our growth in Portugal and Europe. We’re proud to increase our
international export capacity and are looking forward to exporting
dried cannabis as active substances from our EU Campus to legal
jurisdictions in the EU and other international markets,” said
Sascha Mielcarek, Managing Director, Europe. “The next phase of GMP
certification will allow us to utilize the full capacity of our
multi-faceted facility and continue to serve more patients
in-need.”
Tilray was the first medical cannabis producer to successfully
import medical cannabis products into the EU and the first licensed
medical cannabis producer in North America to obtain GMP
certification in accordance with EMA standards. Tilray expects the
second phase of GMP certification for its facility in Portugal to
occur in the coming months, which will allow the company to
manufacture and export GMP-certified finished medicinal products
from Portugal to international markets.
About Tilray®Tilray is a global pioneer in the
research, cultivation, production and distribution of cannabis and
cannabinoids currently serving tens of thousands of patients and
consumers in 12 countries spanning 5 continents.
Cautionary note regarding forward-looking statements:
This press release contains “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and “forward-looking information” within the meaning of
Canadian securities laws, or collectively, forward-looking
statements. Forward-looking statements or
forward-looking-information in this press release may be identified
by the use of words such as, “may”, “would”, “could”, “will”,
“likely”, “expect”, “anticipate”, “believe, “intend”, “plan”,
“forecast”, “project”, “estimate”, “outlook” and other similar
expressions, including without limitation statements in respect to
Tilray’s intention to increase production, processing, cultivation
or R&D capacity or launch brands, products and novel form
factors at any of its facilities and Tilray’s expectations relating
to servicing the global cannabis market. Forward-looking statements
are not a guarantee of future performance and are based upon a
number of estimates and assumptions of management in light of
management’s experience and perception of trends, current
conditions and expected developments, as well as other factors that
management believes to be relevant and reasonable in the
circumstances, including assumptions in respect of current and
future market conditions, the current and future regulatory
environment and future approvals and permits. Actual results,
performance or achievement could differ materially from that
expressed in, or implied by, any forward-looking statements in this
press release, and, accordingly, you should not place undue
reliance on any such forward-looking statements and they are not
guarantees of future results. Please see the heading “Risk Factors”
in Tilray’s Quarterly Report on Form 10-Q, which was filed with the
Securities and Exchange Commission and Canadian securities
regulators on May 15, 2019, assumptions, uncertainties and other
factors that may cause actual future results or anticipated events
to differ materially from those expressed or implied in any
forward-looking statements. Tilray does not undertake and
specifically declines any obligation to update any forward-looking
statements that are included herein, except in accordance with
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190523005139/en/
Media: Chrissy Roebuck, +1-833-206-8161,
news@tilray.comInvestors: Katie Turner, +1-646-277-1228,
Katie.turner@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Apr 2023 to Apr 2024